Accolade, INC DEF 14A proxy statements

Transcarent and Accolade announce the expiration of the Hart-Scott-Rodino waiting period, bringing their merger one step closer to completion in the second quarter of 2025.

Accolade, Inc. has agreed to be acquired by Transcarent, Inc. for $7.03 per share in cash, representing a premium over the company's recent trading prices.

Accolade, Inc. is set to be acquired by Transcarent, Inc., with details emerging regarding employee benefits, stock options, and the regulatory approval process.

Transcarent is set to acquire Accolade in a merger aimed at transforming healthcare by combining their complementary services and shared values.

Accolade, Inc. and Transcarent, Inc. have entered into a definitive agreement for Transcarent to acquire Accolade, aiming to create a unified healthcare solution.

Accolade, Inc. is set to be acquired by Transcarent, Inc. in a merger aimed at enhancing their combined capabilities in the healthcare ecosystem.

Accolade, Inc. has entered into a definitive agreement to be acquired by Transcarent, Inc. for $7.03 per share in an all-cash transaction valued at approximately $621 million, including Accolade's net debt.

Transcarent is set to acquire Accolade for $7.03 per share in cash, aiming to create an industry-leading health and care platform.

Accolade, Inc. will hold its Annual Meeting of Stockholders virtually on August 6, 2024, to elect directors, approve executive compensation, and ratify the selection of KPMG LLP as the independent accounting firm.